domingo, 28 de mayo de 2017

'Big data' approaches for novel anti-cancer drug discovery. - PubMed - NCBI

'Big data' approaches for novel anti-cancer drug discovery. - PubMed - NCBI

 2017 Jun;12(6):599-609. doi: 10.1080/17460441.2017.1319356. Epub 2017 May 2.

'Big data' approaches for novel anti-cancer drug discovery.



The development of improved cancer therapies is frequently cited as an urgent unmet medical need. Recent advances in platform technologies and the increasing availability of biological 'big data' are providing an unparalleled opportunity to systematically identify the key genes and pathways involved in tumorigenesis. The discoveries made using these new technologies may lead to novel therapeutic interventions. Areas covered: The authors discuss the current approaches that use 'big data' to identify cancer drivers. These approaches include the analysis of genomic sequencing data, pathway data, multi-platform data, identifying genetic interactions such as synthetic lethality and using cell line data. They review how big data is being used to identify novel drug targets. The authors then provide an overview of the available data repositories and tools being used at the forefront of cancer drug discovery. Expert opinion: Targeted therapies based on the genomic events driving the tumour will eventually inform treatment protocols. However, using a tailored approach to treat all tumour patients may require developing a large repertoire of targeted drugs.


No hay comentarios:

Publicar un comentario